The long-term OS and PFS benefits of Tα1 in LC patients have been confirmed, and Tα1 also has the potential to reduce complications, restore immune function, and improve quality of life in the short term after surgery, so future clinical studies are needed to determine whether Tα1 can be used postoperatively to further enhance the effect of ERAS. Here, TAAR1 is linked to laryngotracheoesophageal cleft.